Abnormal conditions or the prostate constitute a major medical problem in the United States. Prostatitis, benign enlargement (BPH), and malignant growth of the prostate (CaP), will effect the lives of most men over the age of 50. BPH is a bothersome abnormal growth that fortunately is readily treated by a variety of options. Prostate cancer, if detected early is curable. However, metastatic disease can be fatal, as there is currently no available curative therapy for metastatic prostate cancer. In addition, because of the extreme heterogeneity with regard to the biologic potential of prostatic cancer, there is debate on the approach to therapy, even with localized disease. There is a lack of consensus and viable approaches to management and therapy for CaP. This reflects our lack of knowledge regarding the biologic determinants responsible for this spectrum of behavior at a level that would provide appropriate therapeutic intervention. This O'Brien Urology Center project will focus its attention on determining changes in the cellular phenotype that is associated with disease progression from normal to premalignant lesions, to localized cancer, and to distant disseminated disease. In this project we will center on three areas related to cellular signaling and cell cycle programming as it related to benign and malignant prostate growth. The first project will focus its research efforts on cell cycle regulation in prostate cancer progression. The second project will examine alterations in PKC isozyme signaling in metastatic progression and in apoptotic cell death. The third project will examine the role of PSM antigen as a folate hydrolase in the biology of the prostate and its evolution to cancer. These projects and the recruitment of developmental programs to the Center are designed to provide an understanding of the biology of progression of CaP and developing strong rational for innovative interventional strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Specialized Center (P50)
Project #
2P50DK047650-06
Application #
2716733
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (M1))
Project Start
1993-09-30
Project End
2003-08-31
Budget Start
1998-09-28
Budget End
1999-08-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Yin, Lihong; Bennani-Baiti, Nabila; Powell, C Thomas (2005) Phorbol ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway. J Biol Chem 280:5533-41
Hedvat, Cyrus V; Teruya-Feldstein, Julie; Puig, Pere et al. (2005) Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 13:237-42
Gregor, Polly D; Wolchok, Jedd D; Turaga, Vandana et al. (2005) Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 116:415-21
Gregor, Polly D; Wolchok, Jedd D; Ferrone, Cristina R et al. (2004) CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22:1700-8
O'Keefe, Denise S; Bacich, Dean J; Heston, Warren D W (2004) Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 58:200-10
Ghosh, Arundhati; Heston, Warren D W (2003) Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate 57:140-51
Drobnjak, Marija; Melamed, Jonathan; Taneja, Samir et al. (2003) Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 9:2613-9
Puig, Pere; Capodieci, Paola; Drobnjak, Marija et al. (2003) p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res 9:5642-51
Chang, Sam S; Heston, Warren D W (2002) The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol 7:7-12
Di Como, Charles J; Urist, Marshall J; Babayan, Irina et al. (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8:494-501

Showing the most recent 10 out of 50 publications